Sign In
Buy IKT
$2.18
-0.1000 (-4.39%)
At Close: Jul 31, 2026
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
08:00am, Thursday, 01'st Apr 2021
ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) an
Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference
08:05am, Monday, 22'nd Feb 2021
ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related dis
ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and rela
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
03:43pm, Saturday, 16'th Jan 2021
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related diso
Inhibikase Therapeutics Announces Closing of Initial Public Offering
10:33am, Monday, 28'th Dec 2020
ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related d
